Toray Rapros for Cats has four pharmacological effects: protective effects on vascular endothelial cells; vasodilatory effects; suppressive effects on production of inflammatory cytokines; and antiplatelet effects.
Rapros acts by suppressing ischemia and fibrosis through suppression of capillary decrease, suppression of interstitial inflammation and suppression of microthrombi formation.
Properties
- First veterinary drug approved for the indication of “suppression of deterioration of renal function”.
- Evaluation by the veterinarian and owner has shown that Rapros improves QOL in cats with CKD, leading to high owner adherence to the treatment.
- Small tablet to reduce the burden of everyday treatment.
- Rapros improves anorexia in feline CKD. It also suppresses weight body loss and improve hypoactivity.
- Chronic kidney disease requires lifelong management, it is high safety confirmed in clinical trial.
- Suitable for cats with IRIS stage II-III CKD, inhibiting the deterioration of renal function and improving clinical symptoms.
Rapros is currently approved for use in Japan and in Hong Kong.
Dosage & Administration:
- 1 tablet twice daily, after meals
Precautions
- Rapros is contraindicated in cats with hemorrhage or bleeding tendency.
- A mild heart rate increase within the reference range may occur within 1 hour after administration.
This effect is dose-dependent and may be avoided by reducing the dose. In rare cases, moderate anorexia may be observed.
Rapros is for use in cats only.
Do not administer to pregnant cats or cats that may be pregnant, as Safety of Rapros has not been established.